GC Biopharma Corp. (KRX:006280)
South Korea
· Delayed Price · Currency is KRW 129,300
+1,000 (0.78%)
At close: Jun 20, 2025, 3:30 PM KST
GC Biopharma Revenue
GC Biopharma had revenue of 383.78B KRW in the quarter ending March 31, 2025, with 7.56% growth. This brings the company's revenue in the last twelve months to 1.71T, up 4.46% year-over-year. In the year 2024, GC Biopharma had annual revenue of 1.68T with 3.27% growth.
Revenue (ttm)
1,706.86B
Revenue Growth
+4.46%
P/S Ratio
0.86
Revenue / Employee
849.61M
Employees
2,009
Market Cap
1,475.72B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1,679.89B | 53.25B | 3.27% |
| Dec 31, 2023 | 1,626.64B | -84.67B | -4.95% |
| Dec 31, 2022 | 1,711.31B | 173.49B | 11.28% |
| Dec 31, 2021 | 1,537.83B | 33.71B | 2.24% |
| Dec 31, 2020 | 1,504.12B | 147.00B | 10.83% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,898.69B |
| Celltrion | 3,662.23B |
| ALTEOGEN | 151.65B |
| Yuhan | 2,114.76B |
| SK Biopharmaceuticals | 578.00B |
| HLB Co., Ltd. | 74.64B |
| PharmaResearch | 392.31B |
| Peptron | 4.30B |